- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04466969
Assessment of Hyperkalemia's Illness and Treatment Burden in Chronic Kidney Disease and Heart Failure Patients: HK Registry Pilot Study (HKRegistrypilo)
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Aichi
-
Nagoyashi, Aichi, Japan, 457-8511
- Research Site
-
-
Chiba
-
Matsudoshi, Chiba, Japan, 271-0077
- Research Site
-
-
Fukuoka
-
Iizukashi, Fukuoka, Japan, 820-8505
- Research Site
-
-
Ibaraki
-
Sashimagun, Ibaraki, Japan, 306-0433
- Research Site
-
Tsuchiurashi, Ibaraki, Japan, 300-0028
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
This study will include patients with hyperkalemia treated at outpatient clinics. Eligible patients will be screened through the regular visit to study sites in a consecutive manner. This study will be conducted in outpatient clinics in general hospitals. 150 hyperkalemia patients with CKD or HFrEF will be enrolled and assessed cross-sectionally.
After the written informed consent, subjects will be asked to complete the questionnaire-based survey.
Health-Related Quality of Life (HR-QoL), compliance to treatment with potassium binders, and other factors including age, sex, height, weight, smoking status, alcohol use and socio-economic status will be collected through the designated questionnaires. Information on disease status and on treatment patterns will be collected from physicians, and the latest results of laboratory tests will be collected from medical records (within 6 months before enrolment).
Description
Inclusion Criteria:
- Outpatients aged ≥20 years
Hyperkalemia patients defined as meeting either of the following criteria:
- Having a history of S-K ≥5.1 mmol/L ≥2 times within 6 months before enrolment
- Having a history of S-K ≥5.5 mmol/L once within 6 months before enrolment
- Currently treated by potassium binders for the treatment of hyperkalemia at enrolment
- Having been diagnosed as CKD (≥stage 3b) or HFrEF by investigators as defined below:
CKD is diagnosed based on the guidelines of CKD issued by the Japanese Society of Nephrology (JSN, 2018) as being either or both of condition 1 and 2 for ≥3 months
- Clear sign of kidney impairment based on urinalysis, imaging, blood test, or biopsy. Especially, existence of ≥0.15 g/gCr of proteinuria (≥30 mg/gCr of albuminuria) is important.
- GFR <45 mL/min/1.73m2 Within the routine clinical practice, GFR is estimated by serum creatinine, gender, and age using following the formulation.
eGFR creat (mL/min/1.73m2) = 194 x serum creatinine (mg/dL)-1.094 x age (years)-0.287 (for female patients, x 0.739)
≥Stage 3b CKD is diagnosed based on the following eGFR categories:
- Stage 3b: 30 mL/min/1.73m2 ≤ eGFR <45 mL/min/1.73m2
- Stage 4: 15 mL/min/1.73m2 ≤ eGFR <30 mL/min/1.73m2
- Stage 5: eGFR <15 mL/min/1.73m2
Patients with HFrEF is enrolled if patients meet following criteria within 6 months:
- EF ≤40%
NYHA class II-IV
- Provision of signed, written, and detailed informed consent
- Signed written informed consent by themselves
Exclusion Criteria:
- Currently on any chronic RRT (including hemodialysis or peritoneal dialysis >30 days, or kidney transplant) within 6 months before enrolment
- Patients with acute kidney injury at enrolment •Patients who took blood transfusion or potassium supplements within 6 months before enrolment
- Active malignancy or life expectancy of less than 6 months.
- Patients who have GI disturbance/chronic diarrhoea/stoma, and investigators determine those affect significantly serum K level
- Patients who have autoimmune disorders, and investigators determine those affect significantly serum K level
- Patients whose lab data have suspicion for pseudohyperkalemia
- Patients who are pregnant, lactating, or planning to become pregnant
- Current participation in interventional studies and/or clinical trials
- Patients who, in the opinion of the investigators, would be unlikely to comply with self-assessments
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
HF
Patients with HF with reduced Ejection Fraction (HFrEF) is enrolled if patients meet following criteria within 6 months:
|
stages of CKD (stage 3b)
CKD is diagnosed based on the following e Glomerular Filtration Rate (eGFR) categories: Stage 3b: 30 mL/min/1.73m2 ≤ eGFR <45 mL/min/1.73m2 |
Stages of CKD (stage 4)
CKD is diagnosed based on the following eGFR categories: 15 mL/min/1.73m2 ≤ eGFR <30 mL/min/1.73m2 |
stages of CKD (stage 5)
CKD is diagnosed based on the following eGFR categories: eGFR <15 mL/min/1.73m2 |
Treated by potassium binders
Patients who have been treated by Potassium Binders
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analyse descriptive statistics of PROs
Time Frame: 4weeks
|
The primary focus of this study is to analyse descriptive statistics of PROs which will be used in the Hyperkalemia registry.
Information on demographics, medical history, treatment patterns, medication compliance, and self-reported questionnaire will be collected.
|
4weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D9480R00030
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperkalemia
-
Centre Integre Universitaire de Sante et Services...Canadian Institutes of Health Research (CIHR)Not yet recruitingHyperkalemia, Diminished Renal ExcretionCanada
-
AstraZenecaCompletedHyperkalemia Elevated Plasma K+ Cardiovascular Disease (CVD)Russian Federation
-
University of California, IrvineRecruitingAcute Hyperkalemia | Oral Potassium BindersUnited States
-
Vifor Pharma, Inc.RecruitingHyperkalemiaUnited States, Israel
-
University of AleppoRecruitingHyperkalemiaSyrian Arab Republic
-
Portsmouth Hospitals NHS TrustVifor PharmaRecruitingHyperkalemiaUnited Kingdom
-
Waterstone Pharmaceutical (Wuhan) Co., LTD.Completed
-
AstraZenecaCompletedHyperkalemiaUnited States, Russian Federation, Italy, Denmark
-
ZS Pharma, Inc.CompletedHyperkalemiaUnited States, Australia
-
The University of Texas Health Science Center,...Memorial Hermann HospitalCompleted